Non‐cystic fibrosis bronchiectasis Pipeline

DelveInsight’s, “Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Non-Cystic Fibrosis Bronchiectasis Understanding

Non-Cystic Fibrosis Bronchiectasis Overview

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive lung disease defined by permanent, abnormal dilation of the bronchi, leading to impaired mucociliary transport, chronic airway infection, and inflammation. Unlike cystic fibrosis, NCFB is a heterogeneous condition often resulting from various infectious or inflammatory causes, rather than a single genetic mutation. It can occur due to various factors, including pneumonia, abnormalities of cilia, and immune deficiencies. It most frequently affects the elderly. Patients suffering from NCFB generally experience increased morbidity and worse quality of life.
NCFB is characterized by symptoms that often develop gradually over months or years and tend to worsen over time. The hallmark features include a persistent daily cough and chronic production of mucus. Patients may also experience chest pain, shortness of breath, and wheezing during breathing. Additional symptoms can include fatigue, recurrent fevers or chills, and in some cases coughing up blood or blood-streaked mucus (hemoptysis). As the disease progresses, physical signs such as clubbing thickening of the skin under the fingernails and toenails may also occur, reflecting chronic respiratory impairment. 

NCFB is driven by a self-perpetuating cycle of impaired mucociliary clearance, chronic infection, and persistent inflammation. Dysfunction in airway clearance allows mucus to accumulate and pathogens to persist, triggering a predominantly neutrophilic inflammatory response. The release of inflammatory mediators and proteolytic enzymes progressively damages the bronchial walls, leading to irreversible airway dilation, reduced elasticity, and further impairment in mucus clearance. This “vicious cycle” promotes recurrent infections, ongoing airway injury, and gradual decline in lung function.

The etiology of NCFB is diverse and often multifactorial. It can arise from underlying conditions that impair immune defense or airway function, including autoimmune diseases, immunodeficiency disorders such as HIV or diabetes, and disorders affecting ciliary function responsible for clearing mucus. Hypersensitivity reactions such as allergic bronchopulmonary aspergillosis, as well as chronic pulmonary aspiration due to swallowing dysfunction, can also contribute to airway inflammation and damage. Additionally, respiratory conditions like COPD and alpha-1 antitrypsin deficiency are recognized contributors. Systemic inflammatory disorders, including inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, have also been associated with NCFB. Recurrent or severe respiratory infections such as pneumonia, pertussis (whooping cough), tuberculosis, and fungal infections are major causes, as they directly damage airway walls and initiate the pathological process.

The diagnosis of NCFB requires a thorough clinical evaluation, as the condition is often underdiagnosed and may be mistaken for other respiratory diseases. Assessment typically begins with a detailed medical and family history, along with blood tests to identify underlying causes or associated conditions. Imaging plays a central role, with high-resolution CT scans being the most common and definitive method to confirm bronchiectasis, while chest X-rays may provide initial indications. Additional investigations include lung function tests to evaluate respiratory capacity, sputum cultures to detect bacterial infections, and sweat testing to rule out cystic fibrosis when clinically indicated.

Management of NCFB is focused on controlling symptoms, preventing disease progression, and improving quality of life. Key treatment goals include managing underlying conditions, preventing recurrent infections, facilitating mucus clearance, and reducing the frequency of exacerbations. Therapeutic approaches typically involve a combination of pharmacologic treatments (such as antibiotics and inhaled therapies), adequate hydration, and chest physiotherapy to aid mucus removal. In patients with low oxygen levels, oxygen therapy may be required, while surgical intervention can be considered in selected cases with localized disease or severe complications such as recurrent bleeding.

"Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis (NCFB) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis (NCFB) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Non-Cystic Fibrosis Bronchiectasis Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis (NCFB) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Analysis

This segment of the Non-Cystic Fibrosis Bronchiectasis (NCFB) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs

HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 is a novel, oral, irreversible dipeptidyl peptidase-1 (DPP-1) inhibitor being developed by Haisco Pharmaceutical for treating neutrophil-mediated chronic inflammatory diseases, particularly non-cystic fibrosis bronchiectasis. It aims to reduce neutrophil-driven inflammation and exacerbations. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

CSL787: CSL Behring

CSL787 is a novel, nebulized 10% human plasma-derived polyvalent immunoglobulin G (IgG) solution being developed by CSL Behring to treat chronic lung infections, specifically in non-cystic fibrosis bronchiectasis (NCFB) patients. It uses a customized vibrating-mesh nebulizer for targeted, non-invasive delivery to the airways. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

Galvokimig: UCB S.A.

Galvokimig is a multispecific antibody based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways.   It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

Further product details are provided in the report……..

Non-Cystic Fibrosis Bronchiectasis Drug Therapeutic Assessment

This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs segregated based on following parameters that define the scope of the report, such as:

Major Non-Cystic Fibrosis Bronchiectasis Players in Non-Cystic Fibrosis Bronchiectasis 

There are approx. 15+ key companies which are developing the therapies for Non-Cystic Fibrosis Bronchiectasis (NCFB). The companies which have their Non-Cystic Fibrosis Bronchiectasis (NCFB) drug candidates in the most advanced stage, i.e. Phase III include, Haisco Pharmaceutical Group Co., Ltd.

Non-Cystic Fibrosis Bronchiectasis Clinical Trial Phases

DelveInsight’s report covers around 16+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Non-Cystic Fibrosis Bronchiectasis Drug Route of Administration

Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Non-Cystic Fibrosis Bronchiectasis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Non-Cystic Fibrosis Bronchiectasis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Cystic Fibrosis Bronchiectasis Clinical Trial Activities

The Non-Cystic Fibrosis Bronchiectasis Pipeline report provides insights into different Non-Cystic Fibrosis Bronchiectasis Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic drugs key players involved in developing key drugs.

Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities

The Non-Cystic Fibrosis Bronchiectasis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs.

Non-Cystic Fibrosis Bronchiectasis Pipeline Report Insights

• Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment
• Non-Cystic Fibrosis Bronchiectasis Unmet Needs
• Impact of Non-Cystic Fibrosis Bronchiectasis Drugs

Non-Cystic Fibrosis Bronchiectasis Pipeline Report Assessment

• Non-Cystic Fibrosis Bronchiectasis Pipeline Product Profiles
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment
• Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment
• Non-Cystic Fibrosis Bronchiectasis Inactive drugs assessment
• Non-Cystic Fibrosis Bronchiectasis Market Unmet Needs

Key Questions Answered In the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs?
• How many Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis (NCFB) and their status?
• What are the key designations that have been granted to the emerging drugs?

Non-Cystic Fibrosis Bronchiectasis Key Players

• Haisco Pharmaceutical Group Co., Ltd.
• CSL Limited
• UCB S.A.
• S-INFINITY Pharmaceuticals Co., Ltd
• Reistone Biopharma Company Limited

Non-Cystic Fibrosis Bronchiectasis Key Products

• HSK31858
• CSL787
• Galvokimig
• XH-S004
• RSS0343